AbbVie stock

ABBV · NYSE · USD

Compare AbbVie
$292.82Change from previous close: −0.59%Absolute change: −$1.73

Close · November 17, 2026

Price history

+25.11% over the period

1 year: from $234.00 (November 17, 2025) to $292.75 (November 17, 2026), +25.11%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$292.75
October 30, 2026$294.89
September 30, 2026$261.59
August 31, 2026$256.42
July 31, 2026$250.94
June 30, 2026$251.64
May 29, 2026$217.72
April 30, 2026$211.32
March 31, 2026$217.49
February 27, 2026$232.08
January 30, 2026$223.01
December 31, 2025$228.49
November 28, 2025$227.70
November 17, 2025$234.00

At a glance

  • The company

    Research-based biopharmaceutical company developing and commercializing medicines for autoimmune, inflammatory, cancer, neurological, aesthetic and eye care conditions

  • Latest results

    Quarter to September 30, 2026 · EPS $3.82 (estimate $3.74)

TickerLandia's take on AbbVie

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$190.75
52-wk high$302.93

−3.34% from the 52-week high

Analysts · 29 analysts

Average target$311.81+6.48% vs. price

Buy 23 · Hold 5 · Sell 1 · Buy

TickerLandia Fingerprint: AbbVie

Compared with similar companies: very low risk, very strong momentum, and very low financial strength.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

AbbVie is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), AbbVie's P/E today is 124.0, above the median of its last 10 fiscal years (27.2; between 16.8 and 96.8 from 2016 to 2025). AbbVie's P/E (trailing 12 months): 50.5, +19% against the median of a group of 10 similar companies (42.3).

P/E compared with its history

Compared with 10 similar companies

AbbVie's metrics compared with similar companies
MetricAbbViePosition in the groupBand
P/E (trailing 12 months)50.5High
Forward P/E18.2Middle
Operating margin36.6%High
EV/EBITDA18.6High
Net margin15.7%Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: AbbVie. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$17.4B

Latest quarter · Q3 2026

Net income

$4.22B

Latest quarter · Q3 2026

Quarterly net margin

24.2%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$520.65B
P/E
50.5
EPS
$5.83
Volume
4.71M
Daily trading
€1.35B
Dividend yield
2.36%

How AbbVie is changing

All results
  • Revenue grew 6.0% a year on average over the last 5 years

  • Operating margin fell from 31.2% to 24.6%

  • Shares outstanding up 6.0% in 5 years

Returns

AbbVie returns with dividends

$1,000 invested in AbbVie 5 years ago, on November 17, 2021, would be worth $2,982 today with dividends reinvested: +198.25% in total, +24.43% per year. On price alone it would be $2,495 (+149.47%).

PeriodAbbVieS&P 500$1,000 becomes
1 month+3.56%−3.17%$1,036
6 months+39.18%+0.11%$1,392
Year to date+28.12%+8.34%$1,281
1 year+28.85%+11.15%$1,288
3 years+134.04%+64.30%$2,340
5 years+198.25%+58.18%$2,982
10 years+613.32%+239.10%$7,133

Over the last 6 months it has done better than 78% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

AbbVie: technical analysis

AbbVie is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 0.7% below its all-time closing high ($295.03, November 13, 2026).

Trend
Upward
RSI (14 sessions)
59
Between 30 and 70
vs 200-session average
+21.26%

Active signals

  • The price is moving in an unusually narrow range compared with the last year.

    since November 10, 2026

Support and resistance

Price areas where AbbVie has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$292.82
  3. Support$279.54−4.54%2 touches, last on November 6, 2026
  4. Support$267.02−8.81%4 touches, last on September 23, 2026
  5. Support$260.16−11.15%3 touches, last on October 2, 2026

Volatility and risk

Over the last year it has moved little with the S&P 500.

Beta (1 year) vs S&P 500
−0.00
Volatility (60 sessions, annualised)
19.8%
Largest fall in the last year
−16.46%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

AbbVie: seasonality

Average monthly price change over 14 years

−1.9%Jan+3.9%Feb+0.1%Mar+0.7%Apr+0.4%May+1.9%Jun+1.1%Jul+0.8%Aug+1.5%Sep+1.6%Oct+6.4%Nov+2.6%Dec

Over the last 14 years, the strongest month for AbbVie has been November: +6.38% on average, positive in 10 years out of 13. The weakest has been January: −1.92% on average, positive in 5 years out of 14.

Show chart data
MonthAverageMedianPositive years
January−1.92%−3.38%5 of 14
February+3.91%+3.74%12 of 14
March+0.11%+1.33%10 of 14
April+0.65%+1.26%8 of 14
May+0.42%+0.93%9 of 14
June+1.93%+0.32%7 of 14
July+1.12%+0.78%7 of 14
August+0.84%+1.54%8 of 14
September+1.53%+1.01%8 of 14
October+1.60%+4.15%9 of 14
November+6.38%+7.39%10 of 13
December+2.57%+0.92%9 of 13

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

AbbVie and its competitors

The United States accounts for 76.2% of the sales of AbbVie Inc., while other countries contribute 9.4%, and Germany, Japan, Canada, China, France and the United Kingdom each represent between 1.0% and 2.8%. The company researches, develops, manufactures and sells medicines and therapies worldwide. Its main products include Skyrizi and Rinvoq for autoimmune and inflammatory diseases, Imbruvica, Venclexta and Epkinly for blood cancers, Vraylar for psychiatric disorders, Ubrelvy and Qulipta for migraine, Mavyret for hepatitis C, and Creon, a pancreatic enzyme therapy.

Headquarters
North Chicago, United States
Employees
57,000
Founded
2012
Chief executive
Robert Michael
AbbVie and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
AbbVieABBV$520.65B36.6%50.5+39.18%
Johnson & JohnsonJNJ$680.19B26.6%42.9+22.93%
Merck & Co.MRK$356.13B35.2%144.5+28.72%
AmgenAMGN$250.07B34.1%26.8+40.34%
Eli LillyLLY$1.28T51.3%46.5+40.86%
Gilead SciencesGILD$207.86B38.2%—+31.39%

Same industry or related industries, similar size. Compare AbbVie with its competitors · Full profile